Psychotropic Drugs Reemerging as Headache Medicines.
CNS Drugs September 1, 2024 DOI: 10.1007/s40263-024-01107-x (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Keywords | Psychedelics Headache treatment Alternative medicine Neurological disorders Pain management |
| Citations | 2 |
| Key findings | The therapeutic value of classic psychedelics, ketamine, and cannabinoids for headache disorders requires nuanced consideration of the specific headache disorder, drug, and mode of use. |
Abstract
Scientific and public attention on the therapeutic effects of psychedelics and other psychoactive compounds in headache disorders has recently grown. The use and reported therapeutic effects of such treatments have long been reported, though formal clinical trials are only recently taking place. When considering how these substances might be further studied and eventually applied, it is important to consider the specific headache disorder, the particular drug, and the mode of use. No singular protocol will be applicable across all headache disorders and drugs. In this leading article, the nuance required to consider the value of classic psychedelics, ketamine, and cannabinoids as headache medicines is presented.
Citations in the library
Cites 16
- Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation American Journal of Psychiatry March 17, 2021
- Response of cluster headache to psilocybin and LSD Neurology June 26, 2006
- Maintenance ketamine treatment for depression: a systematic review of efficacy, safety, and tolerability. The Lancet Psychiatry November 1, 2022
- Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin. Neurotherapeutics 2021
- Indoleamine Hallucinogens in Cluster Headache: Results of the Clusterbusters Medication Use Survey Journal of Psychoactive Drugs October 20, 2015
and 11 more in the library